Kea Medical, as a pioneer and forerunner in China's AI-enabled medical device industry, has always been committed to the research, development and commercialization of AI-enabled diagnostic devices and high-value therapeutic devices, and to helping the healthcare industry upgrade its intelligence. The "Deep Vein Fraction DVFFR" developed by Kaya Medical is the world's first CTFFR testing product using deep learning technology, and with this product, Kaya Medical has also become the first medical device company in China to have an AI-enabled medical device Class III license.
Before the birth of the CTFFR detection means, the detection of coronary heart disease often has to use the pressure guidewire + catheterization chamber method. This method is an invasive detection method, both for the operator's technical requirements and the patient's physical requirements are very high. Moreover, the pressure guidewire used for the test is a disposable consumable, which costs about 10,000 dollars for one use, and it also puts certain requirements on the financial ability of the patient. Therefore, this test method has not been widely promoted in the clinic.
Compared with the traditional method of using pressure guidewires to measure FFR values, the emergence of CTFFR, a non-invasive means of detecting coronary heart disease, is undoubtedly a huge step forward. But the non-intelligent CTFFR test products also have to bear a huge amount of arithmetic and complex arithmetic process. Often it takes about 4H to produce a test result.
Intelligent non-invasive CTFFR detection products "deep pulse fraction DVFFR" in the clinical application, completely subverted the detection of coronary heart disease is a heavy work of this status quo. It combines key technologies from artificial intelligence, medical imaging, biomedical engineering and other related disciplines, covering a number of cutting-edge deep learning algorithms independently developed by Kaya Medical, and intelligently optimizes all aspects of medical image processing, model reconstruction and FFR calculation, which improves segmentation accuracy and robustness, and at the same time, greatly improves the processing speed, and the calculation time for completing a test sample is only 10 minutes, which greatly improves coronary heart disease detection and improves the quality of coronary heart disease detection, which is a very important part of coronary heart disease detection. It takes only about 10 minutes to complete the calculation of a test sample, which greatly improves the efficiency of coronary heart disease detection.
The clinical application of the intelligent non-invasive CTFFR test product "Deep Vein Fraction DVFFR" not only improves the work efficiency of doctors, but also reduces the mental, physical and economic burden of patients. The application of this product in the clinic, so that the detection of coronary heart disease into the "fast era", the cause of China's health care and the orderly development of national health insurance have a positive role.